Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 281, Issue 1, 1997, Pages 304-314

  Chu, Xiao Yan ^a   Kato, Yukio ^a   Niinuma, Kayoko ^a   Sudo, Ken Ichi ^b   Hakusui, Hideo ^b   Sugiyama, Yuichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN DERIVATIVE; DRUG METABOLITE; IRINOTECAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANION TRANSPORT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BILIARY EXCRETION; CANCER CHEMOTHERAPY; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG CLEARANCE; DRUG EXCRETION; DRUG GLUCURONIDATION; GASTROINTESTINAL TOXICITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANION TRANSPORT PROTEINS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BILE; BILE CANALICULI; CAMPTOTHECIN; CARRIER PROTEINS; HYPERBILIRUBINEMIA; MALE; RATS; RATS, MUTANT STRAINS; RATS, SPRAGUE-DAWLEY;

EID: 0030959378     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. AKERBOOM, T. P. M., NARAYANASWAMI, V., KUNST, M. AND SIES, H.: ATP-dependent S-(2,4-dinitrophenyl) glutathione transport in canalicular plasma membrane vesicles from rat liver. J. Biol. Chem. 266: 13147-13152, 1991.
2. ARAKI, E., ISHIKAWA, M., Iwo, M., IIGO, T., ITABASHI, M. AND HOSHI, A.: Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitonoal administration of CPT-11. Jpn. J. Cancer Res. 84: 697-702, 1993.
3. ATSUMI, R., SUZUKI, W. AND HAKUSUI, H.: Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. Xenobiotica 21: 1159-1169, 1991.
4. BALLATORI, N. AND TRUONG, A. T.: Multiple canalicular transport mechanisms for glutathione S-conjugates J. Biol. Chem. 270: 3594-3601, 1995.
5. BURKE, T. G. AND MI, Z.: The structural basis of camptothecin interactions with human serum albumin: Impact on drug stability, J. Med. Chem. 37: 40-46, 1994.
6. FASSBERG, J. AND STELLA, V. J.: A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J. Pharm. Sci. 81: 676-684, 1992.
7. FERNANDEZ-CHECA, J. C., TAKIKAWA, H., HORIE, T., OOKHTENS, M. AND KAPLOWITZ, N.: Canalicular transport of reduced glutathione in normal and mutant Eisai hyperbilirubinemic rats. J. Biol. Chem. 267: 1667-1673, 1992.
8. GUPTA, E., LESTINGI, T. M., MICK, R., RAMIREZ, J., YOKES. E. E. AND RATAIN, M. J.: Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea. Cancer Res. 54: 3723-3725, 1994.
9. HERTZBERG, R. P., CARANFA, M. J., HOLDEN, K. G., JAKAS, D. R., GALLAGHER, G., MATTERN, M. R., MONG, S. M., BARTUS, J. O., JOHNSON, R. K. AND KINGSBURY, W. D.: Modification of the hydroxyl lactone ring of camptothecin: Inhibition of mammalian topotaomerase I and biolugical activity. J. Med. Chem. 32: 715-720, 1989.
10. ISHIKAWA, T., MULLER, M., KLUNEMANN, C., SCHAUB, T. AND KEPPLER, D.: ATP-dependent primary active transport of cysteinyl leukotrienes across liver canalicular membrane J. Biol. Chem. 265: 19279-19286, 1990.
11. KANEDA, N., NAGATA, H., FURUTA, T. AND YOKOKURA, T.: Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res. 50: 1715-1720, 1990.
12. KANEDA, N. AND YOKOKURA, T.: Nonlinear pharmacokinetics of CPT-11 in rats. Cancer Res. 50: 1721-1725, 1990.
13. KAWATO, Y., AONUMA, M., HIROTA, Y., KUGA, H. AND SATO, K.: Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 51: 4187-4191, 1991.
14. KIM, R., HIRABAYASHI, N., NISHIYAMA, M., JINUSHI, K., TOGE, T. AND OKADA, K.: Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice. Int. J. Cancer 50: 760-706, 1992.
15. KOBAYASHI, K., SOGAME, Y., HARA, H. AND HAYASHI, K.: Mechanism of glutathione S-conjugate transport in canalicular and basolateral rat liver plasma membranes. J. Biol. Chem. 265: 7737-7741, 1990.
16. KOJIMA, A., SHINKAI, T. AND SAIJO, N.: Cytogenetic effects of CPT-11 and its active metabolite, SN-38, on human lymphocytes, Jpn. J. Clin. Oncol. 23: 116-122, 1993.
17. LOKIEC, F., CANAL, P., GAY, C., CHATELUT, E., ARMAND, J. P., ROCHK, H., BUGAT, R., GONCALVES, E. AND MATHICU, B. A.: Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine. Cancer Chemother. Pharmacol. 36: 79-82, 1995.
18. MIYASAKA, T., MUTAI, M., SAWADA, S., NOKADA, K. AND HAGIWARA, H.: Synthesis of new camptothecin derivatives. Japanese Patent Kokai 56: 758-786, 1981.
19. NAGATA, H., KANEDA, N., FURUTA, T., SAWADA, S., YOKOKURA, T., MIYASAKA, T., FUKUDA, M. AND NOTARE, K.: Action of 7-ethylcampwthecin on tumor cells and its disposition in mice. Cancer Treat. Rep. 71: 341-348, 1987.
20. NEGORO, S., FUKUOKA, M., MASUDA, N., TAKAUA, M., KUSLNOKI, Y., MATSUI, K., TAKIFUJI, N., KUDOH, S., NIITANI, H. AND TAGUCHI, T.: Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J. Natl. Cancer Inst. 83: 1164-1168, 1991.
21. NISHIDA, T., HARDENBROOK, C., GATMAITAN, Z. AND ARIAS, I. M.: ATP-dependent organic anion transport system in normal and TR rat liver canalicular membranes. Am. J. Physiol. 258: G629-G638, 1992.
22. OHE, Y., SASAKI, Y., SHINKAI, T., EGUCHI, K., TAMURA, T., KOJIMA, A., KUNIKANE, H., OKAMOTO, H., KAKATO, A., OHMATSU, H., KANZAWA, F. AND SAIJO, N.: Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J. Natl. Cancer Inst. 84: 972-974, 1992.
23. OHNO, R., OKADA, K., MASAORA, T., KURAMOTO, A., ARIMA, T., YOSHIDA, Y., ARFYOSHI, H., ISHIMAHU, M., SAKAI, Y., OGURO, M., ITO, Y., MORISHIMA, Y., YOKOMAKU, S. AND OTA, K.: An early phase II study of CPT-11, a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J. Clin. Oncol. 8: 1907-1912, 1990.
24. PIKIULA, S., HAYDEN, J. B., AWASTHI, S., AWASTHI, Y. C. AND ZIMNIAK, P.: Organic anion-tranaporting ATPase of rat liver. J. Biol. Chem. 269: 27566-27573, 1994.
25. RIVORY, L. P. AND ROBERT, J.: Reversed-phaue high-performance liquid Chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolites SN-38 in plasma. J. Chromatogr. B 661: 133-141, 1994.
26. RIVORY, L. P. AND ROBERT, J.: Identification and kinetics of a β-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan. Cancer Chemother, Pharmacol. 36: 176-179, 1995.
27. ROTHENBERG, M. L., KUHN, J. G., BURRIS, H. A., III, NELSON, J., ECKAUDT, J. R., TRISTAN-MORALES, M., HILSENBECK, S. G., WEISS, G. R., SMITH, L. S., RODRIGUEZ, G. I., ROCK, M. K. AND VON HOFF, D. D.: Phase I and pharmacokinetic trial of weekly CPT-11. J. Clin. Oncol. 11: 2194-2204, 1993.
28. ROWINSRY, E. K., GROCHOW, L. B., ETTINGKR, D. S., SARTORIUS, S. E., LUBEJKO, B. G., CHEN, T. L., ROCK, M. K. AND DONEHOWEH, R. C.: Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res. 54: 427-436, 1994.
29. SASAKI, Y., HAKUSUI, H., MIZUNO, S., MORITA, M., MIYA, T., EGUCHI, K., SHINKAI, T., TAMURA, T., OHE, Y. AND SAIJO, N.: A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38. Jpn. J. Cancer Res. 86: 101-110, 1995a.
30. SASAKI, Y., YOSHIDA, Y., SUDOH, K., HAKUSUI, H., FUJII, H., OHTSU, T., WAKITA, H., IGARASHI, T. AND ITOH, K.: Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11. Jpn. J. Cancer Res. 86: 111-116, 1995b.
31. SATHIRAKUL, K., SUZUKI, H., YAMADA, T., HANANO, M. AND SUGIYAMA, Y.: Multiple transport systems for organic anions across the bile canalicular membrane, J. Pharmacol. Exp. Ther. 268: 65-73, 1994.
32. SATHIRAKUL, K., SUZUKI, H., YASUDA, K., HANANO, M., TAGEYA, O., HORIE, T. AND SUGIYAMA, Y.: Kinetic analysis of hepatobiliary transport of organic anions in Eisai hyperbilirubinemic mutant rats J. Pharmacol. Exp. Ther. 265: 1301-1312, 1993.
33. + -ATPase activity. J. Lab. Clin. Med. 93: 790-799, 1979.
34. SHIMAMURA, H., SUZUKI, H., HANANO, M., SUZUKI, A., TAGEYA, O., HORIE, T. AND SUGIYAMA, Y.: Multiple systems for the biliary excretion of organic anions in rats: Liquiritigenin conjugates as model compounds. J. Pharmacol. Exp. Ther. 271: 370-378, 1994.
35. SLICHENMYER, W. J., ROWINSKY, E. K., DONEHOWER, R. C. AND KAUFMANN, S. H.: The current status of camptothecm analogues as antitumor agents. J. Natl. Cancer Inst. 85: 271-291, 1993.
36. TAKASUNA, K., KASAI, Y., KITANO, Y., MORI, K., KAKIHATA, K., HIROHASHI, M. AND NOMURA, M.: Study on the mechanisms of diarrhea induced by a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats. Folia Pharmacol. Jpn. 105: 447-460, 1995a.
37. TAKASUNA, K., KASAI, Y., KITANO, Y., MORI, K., KOBAYASHI, R., HAGIWARA, T., KAKIHATA, K., HIROHASHI, M., NOMURA, M., NAGAI, E. AND KAMATAKI, T.: Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats. Jpn. J. Cancer Res. 86: 978-984, 1995b.
38. TAKENAKA. O., HORIE, T., SUZUKI, H. AND SUGIYAMA, Y.: Different biliary excretion systems for glucuronide and sulfate of a model compound: Study using Eisai hyperbilirubinemic rats. J. Pharmacol. Exp. Ther. 274: 1362-1369. 1995a.
39. TAKENAKA, O., HORIE, T., KOBAYASHI, K., SUZUKI, H. AND SUGIYAMA, Y.: Kinetic analysis of hepatobiliary transport for conjugated metabolites in the perfused liver of mutant rats (EHBR) with hereditary conjugated hyperbilirubinemia. Pharm. Res. 12: 1746-1755, 1995b.
40. TANIZAWA, A., FUJIMORI, A., FUJIMORI, Y. AND POMMIER, Y.: Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J. Natl. Cancer Inst. 86: 836-842, 1994.
41. YACHI, K., SUGIYAMA, Y., SAWADA, Y., IGA, T., IKEDA, Y., TODA, G. AND HANANO, M.: Characterization of rose bengal binding to sinusoidal and canalicular plasma membrane from rat liver. Biochim. Biophys. Acta 978: 1-7, 1989.
42. YAMAZAKI, M., SUZUKI, H. AND SUGIYAMA Y.: Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics. Pharm. Res. 13: 497-513, 1996.